John Peter Gutfreund - Net Worth and Insider Trading

John Peter Gutfreund Net Worth

The estimated net worth of John Peter Gutfreund is at least $17,093 dollars as of 2023-06-07. John Peter Gutfreund is the Director of OncoCyte Corp and owns about 75,000 shares of OncoCyte Corp (OCX) stock worth over $17,093. Details can be seen in John Peter Gutfreund's Latest Holdings Summary section.

Transaction Summary of John Peter Gutfreund


John Peter Gutfreund Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Peter Gutfreund owns 1 companies in total, including OncoCyte Corp (OCX) .

Click here to see the complete history of John Peter Gutfreund’s form 4 insider trades.

Insider Ownership Summary of John Peter Gutfreund

Ticker Comapny Transaction Date Type of Owner
OCX OncoCyte Corp 2022-07-28 director

John Peter Gutfreund Latest Holdings Summary

John Peter Gutfreund currently owns a total of 1 stock. John Peter Gutfreund owns 75,000 shares of OncoCyte Corp (OCX) as of December 23, 2022, with a value of $17,093.

Latest Holdings of John Peter Gutfreund

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
OCX OncoCyte Corp 2022-12-23 75,000 0.23 17,093

Holding Weightings of John Peter Gutfreund

John Peter Gutfreund Form 4 Trading Tracker

According to the SEC Form 4 filings, John Peter Gutfreund has made a total of 2 transactions in OncoCyte Corp (OCX) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in OncoCyte Corp is the acquisition of 75,000 shares on December 23, 2022, which cost John Peter Gutfreund around $24,750.

Insider Trading History of John Peter Gutfreund

Insider Trading Shares
Shares Change
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
OncoCyte Corp
OncoCyte Corp
Total 2
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John Peter Gutfreund Trading Performance

GuruFocus tracks the stock performance after each of John Peter Gutfreund's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Peter Gutfreund is -48.44%. GuruFocus also compares John Peter Gutfreund's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Peter Gutfreund within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John Peter Gutfreund's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John Peter Gutfreund

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 5.82 -48.44 -53.67
Relative Return to S&P 500(%) 8.15 -46.24 -50.19

John Peter Gutfreund Ownership Network

Ownership Network List of John Peter Gutfreund

No Data

Ownership Network Relation of John Peter Gutfreund

John Peter Gutfreund Owned Company Details

What does OncoCyte Corp do?

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

Who are the key executives at OncoCyte Corp?

John Peter Gutfreund is the director of OncoCyte Corp. Other key executives at OncoCyte Corp include Interim CEO Josh Riggs , Controller & PAO James Yang Liu , and SVP & Finance & and Interim CFO Anish M. John .

OncoCyte Corp (OCX) Insider Trades Summary

Over the past 18 months, John Peter Gutfreund made 2 insider transaction in OncoCyte Corp (OCX) with a net purchase of 100,000. Other recent insider transactions involving OncoCyte Corp (OCX) include a net purchase of 12,627,028 shares made by Pura Vida Investments, Llc , a net purchase of 415,000 shares made by Andrew Arno , and a net purchase of 32,831,390 shares made by Broadwood Partners Lp .

In summary, during the past 3 months, insiders sold 0 shares of OncoCyte Corp (OCX) in total and bought 27,490,638 shares, with a net purchase of 27,490,638 shares. During the past 18 months, 107,514 shares of OncoCyte Corp (OCX) were sold and 46,334,804 shares were bought by its insiders, resulting in a net purchase of 46,227,290 shares.

OncoCyte Corp (OCX)'s detailed insider trading history can be found in Insider Trading Tracker table.


OncoCyte Corp Insider Transactions

No Available Data

John Peter Gutfreund Mailing Address

Above is the net worth, insider trading, and ownership report for John Peter Gutfreund. You might contact John Peter Gutfreund via mailing address: C/o Oncocyte Corporation, 15 Cushing, Irvine Ca 92618.